Safety and activity of nonpegylated liposomal doxorubicin (nPLD) combined with oral metronomic cyclophosphamide (mC) as preoperative treatment for locally advanced breast cancer (BC) patients (pts).
Daniele Andreis(Istituti Ospitalieri di Cremona), Alberto Bottini(University of Genoa), Letizia Bazzola(Istituti Ospitalieri di Cremona), Giovanni Allevi(Istituti Ospitalieri di Cremona), Sergio Aguggini(Istituti Ospitalieri di Cremona), Ermenegilda Boni(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), Ramona Bertoni(Istituti Ospitalieri di Cremona), Roberto Giardini(Fondazione IRCCS Istituto Nazionale dei Tumori), Chiara Foroni(University of Parma), Manuela Milani(Humanitas University), Vanessa Zanoni(Istituti Ospitalieri di Cremona), Mariarosa Cappelletti(Istituti Ospitalieri di Cremona), Daniele Generali(University of Trieste)
Cited by 0
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
|Cancer Research|2009|298
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
ALK Expression Defines a Distinct Group of T/Null Lymphomas (“ALK Lymphomas”) with a Wide Morphological Spectrum
|American Journal Of Pathology|1998|275